Is BPC-157 Legal in the US?

BPC-157 is not an approved drug in the United States, and it is not a controlled substance either. The FDA has never approved a BPC-157 product for any condition, and the agency has also placed it on the list of bulk substances that compounding pharmacies are barred from using, citing possible safety risks. That combination — not approved, not scheduled, but flagged against compounding — is the actual legal picture, and it is more specific than a flat "legal" or "illegal" answer.

What "legal" actually covers here

Three separate questions get collapsed into "is it legal," and they have three different answers.

• Is it an FDA-approved drug? No. There is no brand-name BPC-157 product with an FDA approval letter, the way Zepbound or Ozempic have one.
• Is it a controlled substance under the DEA's schedules? No. BPC-157 does not appear on any DEA schedule, so possession doesn't carry the same criminal exposure as a Schedule II or III substance.
• Can a licensed pharmacy compound it into a prescription? No, not anymore. The FDA put BPC-157 on its list of bulk drug substances that may present significant safety risks, which means 503A and 503B compounding pharmacies are barred from using it as an ingredient.

That third point is the one most people miss. It's the FDA's actual published answer to "is BPC-157 legal," and it's a narrower statement than either "approved" or "banned."

Why there's no approved BPC-157 drug

BPC-157 is a synthetic peptide derived from a protective protein found in gastric juice, and most of the published research looks at tissue repair — tendon, ligament, and gut healing in animal models. A 2019 review in Gwyer et al., Cell Tissue Res covers the mechanistic work on musculoskeletal repair, and a 2025 systematic review in Vasireddi et al., HSS J looks specifically at what's been published in sports medicine. Both describe a body of animal and in vitro data without a completed human clinical trial program behind it.

No pharmaceutical sponsor has taken BPC-157 through the FDA's drug approval pathway — no Phase 1 safety trial, no Phase 2 dose-finding study, no Phase 3 trial registered for it the way retatrutide or tirzepatide went through theirs. Without that trial record, there is no New Drug Application for the FDA to approve or deny. The molecule simply hasn't gone through the process that produces an approved drug, which is a different situation from a molecule that was studied and rejected.

Why pharmacies can't compound it for you

Before the FDA's bulk drug substances list existed, some compounding pharmacies were mixing BPC-157 into prescriptions on a case-by-case basis under 503A rules. That changed once the FDA added it to the restricted list alongside other research peptides — ipamorelin, GHK-Cu in injectable form, epitalon, KPV, MOTS-c, selank, semax, DSIP, thymosin, and TB-500 are on the same list. The agency's stated concern is that these substances haven't been shown safe and effective for the uses compounders were putting them to, and compounding bypasses the review a drug would otherwise need.

The practical effect: a pharmacist who fills a BPC-157 prescription today is operating outside what the FDA says compounding pharmacies are permitted to do with that ingredient. That's a different problem from the drug being "illegal to possess," but it does mean the normal path of walking into a pharmacy with a prescription isn't available the way it is for an approved medication.

What research material looks like instead

PeptoClinic's BPC-157 is supplied for research purposes, not dispensed through a pharmacy prescription. A physician reviews each consultation before anything ships, and the catalogue — including peptides like GHK-Cu, KPV, and thymosin alpha-1 — follows that same model. None of it is marketed as a treatment for any condition, because none of it has gone through the approval process that would let it be. Current pricing for each compound is on the pricing page; lab reports and what a certificate of analysis actually verifies are covered on the quality page.

How this compares to peptides that did get approved

Not every research peptide is in the same regulatory position. Some molecules in this category exist both as an unapproved research peptide and as an approved brand-name drug for a specific use — tirzepatide is Mounjaro and Zepbound, semaglutide is Ozempic and Wegovy, tesamorelin is Egrifta. BPC-157 isn't one of those: there is no approved brand-name BPC-157 drug on the market, and the material PeptoClinic supplies is not equivalent to, and is not, any approved drug. The full catalog separates these cases out compound by compound rather than treating "peptide" as a single legal category.

Where that leaves someone buying it

The honest summary, without legal advice beyond what's published: BPC-157 is not an FDA-approved drug, it's not a DEA-controlled substance, and it's on the FDA's list of substances pharmacies cannot legally compound. Buying research material isn't the same transaction as filling a prescription, and no seller — PeptoClinic included — can represent it as treating, curing, or preventing anything, because that representation would require the approval it doesn't have.